(DEA) MATE Act - Substance Use Disorder Bundle

In accordance with the Medication Access and Training Expansion (MATE) Act, beginning June 7, 2023, all providers who are registered with the DEA are required to complete 8 hours of training on the treatment and management of patients with opioid and other substance use disorders. This bundle fully satisfies this one-time requirement. 

Total Credits: 9.0 contact hours; 8.5 are pharmacology

Expiration Date: June 30, 2024

$225

  • Includes Credits

    Opioid prescribing can be concerning and frustrating, but they are mainstays of pain treatment. When opioids are appropriate, understanding opioids, how they work, and dosing considerations are vitally important in caring for a patient experiencing pain. This session will focus on opioid mechanism of actions and different opioids, with special considerations that practitioner must take to safely prescribing and treat this patient population | 1.50 credits (1.50 pharmacology) | $37.50

  • Includes Credits

    This presentation will focus on non-opioid therapies for the treatment of both acute and chronic pain. With such scrutiny into pain practice over the last few years, providers need to arm themselves with appropriate therapies for pain. What patient, when and how will be discussed in this section. | 1.50 credits (1.50 pharmacology) | $37.50

  • Includes Credits

    As a result of the opioid crisis, no medical profession has come under more scrutiny, regulatory oversight, and increased legal risk than primary care providers who prescribe opioids. This course will cover DEA’s authority, an overview of current drugs of concerns and emerging drug threats, medical provider and office controlled substance risks along with case studies followed by various drug updates including fentanyl, CBD, Kratom, medication assisted treatment, drug destruction, telemedicine, DEA FAQ’s, DEA provider resources and overall provider risk mitigations safeguards. This isn’t a “theory class” from an attorney who’s never been in the courtroom or one about “recent case rulings” on one about “drug policy analysis”, but a hands-on, data driven, common sense review of problem areas from a former DEA agent with real life opioid experience. | 1.50 credits (1.0 pharmacology) | $40

  • Includes Credits

    Alcohol, marijuana, and tobacco are substances most commonly used by adolescents. Substance use in adolescence becomes risky, when does substance use become substance abuse? This presentation will focus on adolescent substance use and abuse. This presentation will also focus on the most commonly abused substances during adolescence, factors that contribute to substance abuse and treatment plans. | 1.50 credits (1.50 pharmacology) | $40

  • Includes Credits

    Adolescent substance use has followed familiar trends for several decades with alcohol, nicotine, and cannabis leading other drugs in popularity. After several years of declining nicotine use, primarily via combustible cigarettes, recent data suggests a resurgence of nicotine use, primarily via e-cigarettes as well as a marked increase in cannabis use, likely corresponding with legalization efforts. Additionally, there has been an increase in hallucinogen use and the dangers of opioid use have heightened due to the rise of illicit fentanyl being brought in from outside the United States. This lecture will review the most recent Monitoring the Future study and discuss implications of adolescent substance use trends on healthcare providers. | 1.50 credits (1.50 Pharmacology) | $40

  • Includes Credits

    The ongoing opioid epidemic has led to controversy regarding the appropriate treatment of both acute and chronic forms of pain. Avoidance of opioids has led to the potential for inadequate pain management and a potential for increased adverse events related to non-opioid analgesics, specifically NSAIDs. The CDC updated their guidelines for prescribing opioids with the hope of providing more guidance for practitioners about how to safely utilizing these medications. Novel therapies are also being explored as an alternative to opioids and one promising medication is intravenous ketamine. This presentation will review updated guidelines to help determine when and how to safely utilize both opioid and non-opioid analgesics. Additionally, it will explore the potential of IV ketamine for acute pain management. | 1.50 credits (1.50 Pharmacology) | $40